{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:29:49Z","timestamp":1792801789265,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Scientific Research Funding of Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin Key Laboratory of Metabolic Diseases","award":["ZXY-ZDSYS2020-4"],"award-info":[{"award-number":["ZXY-ZDSYS2020-4"]}],"id":[{"id":"https:\/\/ror.org\/02mh8wx89","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scientific Research Funding of Tianjin Medical University Chu Hsien-I Memorial Hospital, Tianjin Key Laboratory of Metabolic Diseases","award":["ZXY-ZDSYSZD2022-1"],"award-info":[{"award-number":["ZXY-ZDSYSZD2022-1"]}],"id":[{"id":"https:\/\/ror.org\/02mh8wx89","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Project of Science and Technology Popularization Activity in Tianjin","award":["22KPHDRC00060"],"award-info":[{"award-number":["22KPHDRC00060"]}]},{"name":"China Endocrine Metabolism Talent Research Fund","award":["2022-N-02-07"],"award-info":[{"award-number":["2022-N-02-07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sodium-dependent glucose transporter 2 inhibitor (SGLT2i) has the advantages of effectively lowering blood glucose levels and improving renal outcomes in diabetic patients. This study evaluated the effect of canagliflozin on intrarenal lipid content and oxygenation in newly diagnosed type 2 diabetes mellitus (T2DM) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 64 newly diagnosed T2DM patients with normal renal function were randomly divided into canagliflozin (n\u2009=\u200933) and glimepiride control (n\u2009=\u200931) groups. All patients underwent functional magnetic resonance imaging (fMRI) scanning to assay patients' intrarenal lipid content and oxygenation level before and after 24\u00a0weeks of treatment. Furthermore, the relationship between body mass index and intrarenal lipid content in T2DM patients was analyzed and the correlation between changes in intrarenal lipid content and improvements in renal hypoxia was further assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The canagliflozin group had a greater decrease in body weight and blood uric acid level than the glimepiride group (all P\u2009&lt;\u20090.05). The intrarenal lipid content could be significantly reduced after canagliflozin treatment for 24\u00a0weeks. The R2* values, a parameter for quantifying the oxygen content in tissues and is inversely related to the oxygen content, of the renal cortex and medulla in the canagliflozin group decreased from the baseline by 6.40% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.01) and 12.09% (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.000007), respectively. In addition, the degree of reduction of fat fraction (\u0394FF) in the kidneys of the canagliflozin group was correlated with the degree of improvement of oxygenation level (\u0394R2*) in the renal cortex (r\u2009=\u20090.422,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The early renal protective effect of SGLT2i in newly diagnosed T2DM patients may be partly attributed to the amelioration of renal hypoxia via the alleviation of ectopic lipid deposition in the kidneys.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial Registration:<\/jats:italic>\n                      Chu Hsien-I Memorial Hospital of Tianjin Medical University (ChiCTR2000037951).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-023-01236-1","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T21:02:05Z","timestamp":1701896525000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sodium-dependent glucose transporter 2 inhibitor alleviates renal lipid deposition and improves renal oxygenation levels in newly diagnosed type 2 diabetes mellitus patients: a randomized controlled trial"],"prefix":"10.1186","volume":"15","author":[{"given":"Li","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongdan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haizhen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhida","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saijun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"issue":"4","key":"1236_CR1","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.pcad.2019.07.003","volume":"62","author":"E Braunwald","year":"2019","unstructured":"Braunwald E. Diabetes, heart failure, and renal dysfunction: The vicious circles[J]. Prog Cardiovasc Dis. 2019;62(4):298\u2013302.","journal-title":"Prog Cardiovasc Dis"},{"key":"1236_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i6505","author":"WM Valencia","year":"2017","unstructured":"Valencia WM, Florez H. How to prevent the microvascular complications of type 2 diabetes beyond glucose control. BMJ. 2017. https:\/\/doi.org\/10.1136\/bmj.i6505.","journal-title":"BMJ"},{"issue":"2","key":"1236_CR3","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nrneph.2015.173","volume":"12","author":"MC Thomas","year":"2015","unstructured":"Thomas MC, Cooper ME, Zimmet P, et al. Changing epideiology of type 2 diabetes mellitus and associated chronic kidney disease[J]. Nat Rev Nephrol. 2015;12(2):73.","journal-title":"Nat Rev Nephrol"},{"key":"1236_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","author":"Y Li","year":"2020","unstructured":"Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association:national cross sectional study. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.m997.","journal-title":"BMJ"},{"issue":"12","key":"1236_CR5","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1236_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.4093\/dmj.2014.38.4.252","volume":"38","author":"CW Park","year":"2014","unstructured":"Park CW. Diabetic kidney disease: from epidemiology to clinical perspectives. Diabetes Metab J. 2014;38(4):252\u201360.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"1236_CR7","first-page":"71","volume":"32","author":"L Ying","year":"2016","unstructured":"Ying L, Liu Yu, Li X, et al. Research progress of ectopic lipid deposition and kidney injury in diabetic kidney disease. Chinese J Nephrol. 2016;32(1):71\u201371.","journal-title":"Chinese J Nephrol"},{"issue":"3","key":"1236_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1148\/radiol.13132179","volume":"269","author":"GR Morrell","year":"2013","unstructured":"Morrell GR, Zhang JL, Lee VS. Science to practice: Renal hypoxia and fat deposition in diabetic neuropathy\u2013new insights with functional renal MR imaging. Radiology. 2013;269(3):625\u20136.","journal-title":"Radiology"},{"issue":"2","key":"1236_CR9","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2215\/CJN.02900313","volume":"9","author":"B Ebrahimi","year":"2014","unstructured":"Ebrahimi B, Textor SC, Lerman LO. Renal relevant radiology: renal functional magnetic resonance imaging. CJASN. 2014;9(2):395\u2013405.","journal-title":"CJASN"},{"issue":"5","key":"1236_CR10","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/13543776.2019.1612879","volume":"29","author":"J Pandey","year":"2019","unstructured":"Pandey J, Tamrakar AK. SGLT2 inhibitors for the treatment of diabetes: a patent review (2013\u20132018). Expert Opin Ther Pat. 2019;29(5):369\u201384.","journal-title":"Expert Opin Ther Pat"},{"issue":"24","key":"1236_CR11","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"15","key":"1236_CR12","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.118.035901","volume":"138","author":"BL Neuen","year":"2018","unstructured":"Neuen BL, Ohkuma T, Neal B, et al. Cardiovascular and renal outcomes with canagliflozin according to baseline kidney function. Circulation. 2018;138(15):1537\u201350.","journal-title":"Circulation"},{"issue":"5","key":"1236_CR13","doi-asserted-by":"publisher","first-page":"717","DOI":"10.2337\/dc16-0041","volume":"39","author":"M Abdul-Ghani","year":"2016","unstructured":"Abdul-Ghani M, Del Prato S, Chilton R, et al. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 2016;39(5):717\u201325.","journal-title":"Diabetes Care"},{"issue":"5","key":"1236_CR14","doi-asserted-by":"publisher","first-page":"101274","DOI":"10.1016\/j.diabet.2021.101274","volume":"47","author":"S Zhou","year":"2021","unstructured":"Zhou S, Zhang Y, Wang T, et al. Canagliflozin could improve the levels of renal oxygenation in newly diagnosed type 2 diabetes patients with normal renal function. Diabetes Metab. 2021;47(5):101274.","journal-title":"Diabetes Metab"},{"issue":"4","key":"1236_CR15","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.kint.2017.10.020","volume":"93","author":"M Pruijm","year":"2018","unstructured":"Pruijm M, Milani B, Pivin E, et al. Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease. Kidney Int. 2018;93(4):932\u201340.","journal-title":"Kidney Int"},{"key":"1236_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1148\/radiology.153.1.6089263","volume":"153","author":"WT Dixon","year":"1984","unstructured":"Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984;153:189\u201394.","journal-title":"Radiology"},{"key":"1236_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1002\/jmri.21492","volume":"28","author":"J Ma","year":"2008","unstructured":"Ma J. Dixon techniques for water and fat imaging. J Magn Reson Imaging. 2008;28:543\u201358.","journal-title":"J Magn Reson Imaging"},{"issue":"24","key":"1236_CR18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. CREDENCE trial investigators canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"4","key":"1236_CR19","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/s41591-022-01703-8","volume":"28","author":"JA Spertus","year":"2022","unstructured":"Spertus JA, Birmingham MC, Nassif M, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022;28(4):809\u201313.","journal-title":"Nat Med"},{"issue":"2","key":"1236_CR20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/jcp.30621","volume":"237","author":"S Ravindran","year":"2022","unstructured":"Ravindran S, Munusamy S. Renoprotective mechanisms of sodium-glucose co-transporter 2 (SGLT2) inhibitors against the progression of diabetic kidney disease. J Cell Physiol. 2022;237(2):1182\u2013205.","journal-title":"J Cell Physiol"},{"key":"1236_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"83","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021;83:503\u201328.","journal-title":"Annu Rev Physiol"},{"issue":"8","key":"1236_CR22","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","volume":"41","author":"MS Kuchay","year":"2018","unstructured":"Kuchay MS, Krishan S, Mishra SK, et al. Effect of Empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial). Diabetes Care. 2018;41(8):1801\u20138.","journal-title":"Diabetes Care"},{"issue":"4","key":"1236_CR23","doi-asserted-by":"publisher","first-page":"414","DOI":"10.23876\/j.krcp.19.063","volume":"38","author":"T Honda","year":"2019","unstructured":"Honda T, Hirakawa Y, Nangaku M. The role of oxidative stress and hypoxia in renal disease. Kidney Res Clin Pract. 2019;38(4):414\u201326.","journal-title":"Kidney Res Clin Pract"},{"key":"1236_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy243","author":"M Pruijm","year":"2018","unstructured":"Pruijm M, Mendichovszky IA, Liss P, et al. Renal blood oxygenation level-dependent magnetic resonance imaging to measure renal tissue oxygenation: a statement paper and systematic review. Nephrol Dial Transplant. 2018. https:\/\/doi.org\/10.1093\/ndt\/gfy243.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1236_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.diabres.2012.11.004","volume":"99","author":"M Pruijm","year":"2013","unstructured":"Pruijm M, Hofmann L, Zanchi A, et al. Blockade of the renin\u2013angiotensin system and renal tissue oxygenation as measured with BOLD-MRI in patients with type 2 diabetes. Diabetes Res Clin Pract. 2013;99(2):136\u201344.","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"1236_CR26","doi-asserted-by":"publisher","first-page":"e95895","DOI":"10.1371\/journal.pone.0095895","volume":"9","author":"P Menno","year":"2014","unstructured":"Menno P, Lucie H, Maciej P, et al. Determinants of Renal Tissue Oxygenation as Measured with BOLD-MRI in Chronic Kidney Disease and Hypertension in Humans. PLoS ONE. 2014;9(4):e95895.","journal-title":"PLoS ONE."},{"key":"1236_CR27","doi-asserted-by":"publisher","first-page":"154918","DOI":"10.1016\/j.metabol.2021.154918","volume":"126","author":"H Liu","year":"2022","unstructured":"Liu H, Sridhar VS, Boulet J, et al. Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease. Metabolism. 2022;126:154918.","journal-title":"Metabolism"},{"key":"1236_CR28","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1111\/dom.14489","volume":"23","author":"H Liu","year":"2021","unstructured":"Liu H, Sridhar VS, Montemayor D, et al. Changes in plasma and urine metabolites associated with empagliflozin in patients with type 1 diabetes. Diabetes Obes Metab. 2021;23:2466\u201375.","journal-title":"Diabetes Obes Metab"},{"issue":"83","key":"1236_CR29","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","volume":"10","author":"V Vallon","year":"2021","unstructured":"Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2021;10(83):503\u201328.","journal-title":"Annu Rev Physiol"},{"issue":"3","key":"1236_CR30","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.kint.2020.02.041","volume":"98","author":"AC Hesp","year":"2020","unstructured":"Hesp AC, Schaub JA, Prasad PV, et al. The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including Q1 SGLT2 inhibitors? Kidney Int. 2020;98(3):579\u201389.","journal-title":"Kidney Int"},{"issue":"13","key":"1236_CR31","doi-asserted-by":"publisher","first-page":"e016173","DOI":"10.1161\/JAHA.119.016173","volume":"9","author":"A Zanchi","year":"2020","unstructured":"Zanchi A, Burnier M, Muller ME, et al. Acute and chronic effects of SGLT2 inhibitor empagliflozin on renal oxygenation and blood pressure control in nondiabetic normotensive subjects: a randomized. Placebo-Controlled Trial J Am Heart Assoc. 2020;9(13):e016173.","journal-title":"Placebo-Controlled Trial. J Am Heart Assoc"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01236-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-023-01236-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-023-01236-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T21:03:07Z","timestamp":1701896587000},"score":1,"resource":{"primary":{"URL":"https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-023-01236-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1236"],"URL":"https:\/\/doi.org\/10.1186\/s13098-023-01236-1","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent has been obtained from each patient after full explanation of the purpose and nature of all procedures used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}